financetom
Business
financetom
/
Business
/
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
Apr 4, 2024 7:20 AM

10:04 AM EDT, 04/04/2024 (MT Newswires) -- James M Daly, Director, on April 01, 2024, sold 32,489 shares in Madrigal Pharmaceuticals ( MDGL ) for $8,218,630. Following the Form 4 filing with the SEC, Daly has control over a total of 1,198 shares of the company, with 1,198 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/xslF345X03/doc4.xml

Price: 246.66, Change: +1.43, Percent Change: +0.58

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neo Signs MOU to Reserve Major Magnet Production Capacity for Bosch
Neo Signs MOU to Reserve Major Magnet Production Capacity for Bosch
Sep 21, 2025
08:03 AM EDT, 09/19/2025 (MT Newswires) -- Neo Performance Materials ( NOPMF ) said Friday it has signed a Memorandum of Understanding with Robert Bosch, agreeing to reserve a significant annual magnet production capacity for the global company. The MOU also outlines a clear mutual target for the partners to transition the capacity reserve into definitive projects, a statement said....
Syndax's Revumenib Added to National Cancer Guidelines for NPM1-Mutant Acute Myeloid Leukemia
Syndax's Revumenib Added to National Cancer Guidelines for NPM1-Mutant Acute Myeloid Leukemia
Sep 21, 2025
08:05 AM EDT, 09/19/2025 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said Friday the National Comprehensive Cancer Network included its blood cancer drug Revuforj, or revumenib, as a category 2A recommendation in the Clinical Practice Guidelines in Oncology for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, an aggressive blood cancer associated with high rates of relapse....
Fathom Holdings Prices Underwritten Public Offering of Common Stock
Fathom Holdings Prices Underwritten Public Offering of Common Stock
Sep 21, 2025
CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. ( FTHM ) , a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase...
Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer
Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer
Sep 21, 2025
08:01 AM EDT, 09/19/2025 (MT Newswires) -- Nuvation Bio ( NUVB ) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer. The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023. The approval...
Copyright 2023-2026 - www.financetom.com All Rights Reserved